Advocacy intelligence hub — real-time data for patient organizations
Opdualag: FDA approved
Treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma
MEKINIST and TAFINLAR: FDA approved
TAFINLAR is indicated, in combination with trametinib, for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection
IMLYGIC: FDA approved
Indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Copay Assistance1
MEKINIST and TAFINLAR
Novartis Pharmaceuticals Corporation
Patient Assistance Programs2
Opdualag
(nivolumab and relatlimab-rmbw)Orphan drugBristol-Myers Squibb Company
Programmed Death Receptor-1 Blocking Antibody [EPC]
12.1 Mechanism of Action Relatlimab is a human IgG4 monoclonal antibody that binds to the LAG-3 receptor, blocks interaction with its ligands, includi...
MEKINIST and TAFINLAR
(trametinib and dabrafenib)Orphan drugNovartis Pharmaceuticals Corporation
IMLYGIC
(talimogene laherparepvec)Orphan drugBioVex, Inc. (subsidiary of Amgen)
12.1 Mechanism of Action IMLYGIC has been genetically modified to replicate within tumors and to produce the immune stimulatory protein GM-CSF. IMLYGI...